Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129824 | 0.83 | CTDSP1 (0.32) | CYP1A2P2RX7NAPRTCCR2CTDSP1 | |
| SCHEMBL31067927 | 0.76 | P2RX7 (0.35) | CYP1A2P2RX7NAPRTCCR2CTDSP1 | |
| SCHEMBL997656 | 0.71 | P2RX7 (0.36) | CYP1A2P2RX7NAPRTCCR2CTDSP1 | |
| SCHEMBL31092383 | 0.71 | GRIN1 (0.40) | CYP1A2 | |
| SCHEMBL2424317 | 0.71 | GABRA1 (0.42) | CYP1A2CTDSP1 | |
| SCHEMBL16235549 | 0.71 | GRIN1 (0.40) | CYP1A2 | |
| SCHEMBL21618135 | 0.70 | P2RX7 (0.34) | CYP1A2P2RX7CTDSP1 | |
| SCHEMBL28443035 | 0.70 | P2RX7 (0.35) | CYP1A2P2RX7NAPRTCCR2CTDSP1 | |
| SCHEMBL907708 | 0.70 | CYP1A2 (0.45) | CYP1A2P2RX7CTDSP1 | |
| SCHEMBL12878804 | 0.70 | CTDSP1 (0.36) | CYP1A2P2RX7CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800631-B2 | STABLE TO BE ADMINISTERED VIA THE DRINKING WATER OF ANIMALS; SHELF-LIFE; PALATABLE ANTIMICROBIAL DRUG CONCENTRATE | STROBEL MICHAEL A (US) | 2004-10-05 | — | — | US | disclosed |
| US-20020183287-A1 | Method of producing a concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution | STROBEL MICHAEL A (US) | 2002-12-05 | — | — | US | disclosed |
| US-6410543-B1 | MICROBIOCIDES; MIXTURE OF ANTIOXIDANT, SWEETENER AND FLAVOR | PHARMACEUTICAL SOLUTIONS, INC. | 2002-06-25 | — | — | US | disclosed |
| US-6211185-B1 | ADMINISTERING ORALLY WITH DRINKING WATER | VETERINARY PHARMACY CORPORATION | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183287-A1 | Method of producing a concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution | DPYD, DUS2, DHPS | CYP1A2 1382/4885P2RX7 284/4885NAPRT 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.